key: cord-1009190-aw2vgzjw
authors: Pensato, Umberto; Muccioli, Lorenzo; Janigro, Damir; Guarino, Maria; Bisulli, Francesca; Cortelli, Pietro
title: Akinetic Mutism in COVID-19-related encephalopathy: a cytokine-mediated maladaptive sickness behavioral response?
date: 2021-05-13
journal: Brain Behav Immun Health
DOI: 10.1016/j.bbih.2021.100272
sha: 115fac66a43f0086c97b1f75428a0c8d55c11099
doc_id: 1009190
cord_uid: aw2vgzjw

nan

Coronavirus disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It primarily causes respiratory symptoms and often presents with flu-like symptoms such as fever, cough, tiredness, and headache. Severe COVID-19 is associated with cytokine storm, an acute systemic hyperinflammatory syndrome defined by elevated circulating cytokine levels and secondary organ dysfunction, including the brain. Herein, we aimed to analyse clinical manifestations of COVID-19-related encephalopathy (CORE) and other cytokine storm-associated encephalopathy (CySE) disorders, with a focus on akinetic-mutism, in a bio-behavioral perspective, suggesting that they may be interpreted as maladaptive sickness behavioral responses caused by cytokine storm.

CORE is a disorder characterized by a predominant electro-clinical frontal lobe dysfunction, whose underlying mechanisms have been partially unravelled [1] [2] [3] [4] . Even though a direct pathogenic role of SARS-CoV-2 was initially proposed, coronavirus RNA is almost invariably undetectable in cerebrospinal fluid (CSF). In addition, CSF analysis, neuroimaging, neuropathological findings, and the clinical response to immunotherapies, argue for an immune-mediated pathogenesis driven by cytokine-mediated neuroinflammation, rather than an infectious agent targeting the brain [1] [2] [3] [4] . Several studies have shown a direct correlation between cytokine storm intensity and severity of neurological manifestations in CORE. Accordingly, common clinical manifestations of CORE, such as delirium, dysexecutive syndrome, and pyramidal signs, are observed in up to 85% of COVID-19 patients in intensive care units 5 . Delirium has also been reported in up to 28% of elderly patients with COVID-19 presenting to the emergency department, especially those J o u r n a l P r e -p r o o f with prior cognitive impairment 6 , yet it may also occur in younger adults with no known comorbidities. Notably, encephalopathy has been reported as a recurrent neurological complication of other cytokine storm disorders, including sepsis and cytokine release syndrome related to chimeric antigen receptor (CAR) T-cells therapy, a novel treatment for refractory malignancies 3, 7 . We recently reviewed these encephalopathies, revealing a remarkable overlap of clinical and investigative features across conditions, suggesting that cytokine storm-associated encephalopathy (CySE) may represent a clinical spectrum of disorders sharing cytokine-mediated neuroinflammation as the overarching underlying mechanism 3 .

Delirium and a frontal lobe dysfunction characterized by expressive aphasia, behavioral abnormalities, dysexecutive syndrome and akinetic mutism have emerged as recurrent presentations in patients with CORE 2-4 . Akinetic mutism is an uncommon neurological manifestation secondary to frontal-subcortical dysfunction, usually related to a brain lesion 8 .

Perhaps surprisingly, it has been reported in the absence of underlying structural brain abnormalities in up to 13% of admitted COVID-19 patients 9 , and is also reported in neurotoxicity related to CAR T-cells therapy, where it represents a distinctive feature 2,3,7 .

Akinetic mutism is characterized by a decrease of goal-directed behavioral and emotional responses, leading to near absence of spontaneous movement (akinetic) or speech (mutism), yet with relatively preserved consciousness 8 

Sickness behavior is an innate, evolutionarily conserved, coordinated behavioral, autonomic and endocrine response shared by mammals confronted with stressors such as predators or Studies in the elderly and individuals with prior cognitive impairment (who are the most at risk of developing sepsis-associated encephalopathy, as well as CORE) have shed light into potential mechanisms leading to maladaptive sickness behavior. These include increased blood-brain barrier permeability and dysfunctional microglia, which may act as an amplifier for neuroinflammation 10 . As cytokine storm-associated encephalopathy has been observed recurrently also in young, cognitively healthy individuals, the maladaptive sickness behavior may be interpreted as an imbalance between systemic inflammation and neuropsychological responses. Therefore, both an exaggerated systemic inflammation in a healthy brain (e.g., COVID-19-associated cytokine storm), or a susceptible brain confronted with a relatively mild inflammatory stimulus (e.g., urinary tract infection in the elderly) may be sufficient to result in a disproportionate cytokine-mediated neuroinflammation, leading to encephalopathy Akinetic mutism in the absence of structural brain lesions, especially if transitory, represents a specific clinical finding of these conditions, possibly reflecting a cytokine-mediated maladaptive sickness behavior.

Although the mass vaccination strategies adopted worldwide will hopefully limit severe COVID-19 cases, acknowledging the pathophysiological mechanisms underpinning akinetic mutism and other neurological manifestations observed in this condition remains of primary importance. Indeed, various immunotherapies investigated in CORE, including steroids, intravenous immunoglobulin and anti-cytokines monoclonal antibodies may have a beneficial role also in other cytokine storm-associated encephalopathies. Elevated cytokine levels, resulting from various potential triggers, including SARS-COV-2 virus, act as neuromodulators informing the hypothalamus about an inflammatory stressor.

The hypothalamus orchestrates adaptive biological responses to restore homeostasis, engendering sickness behavior. Therefore, both an exaggerated systemic inflammation in a healthy brain (e.g., COVID-19-associated cytokine storm) or a susceptible brain confronted with a relatively mild inflammatory stimulus (e.g., urinary tract infection in the elderly) may be sufficient to lead to a disproportionate cytokine-mediated neuroinflammation, leading to encephalopathy.

J o u r n a l P r e -p r o o f

SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses

Covid-19-associated encephalopathy and cytokine-mediated neuroinflammation

Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy

Is the Frontal Lobe the Primary Target of SARS-CoV-2?

Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients

Older Patients With

Presenting to the Emergency Department

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

On the pathophysiology and treatment of akinetic mutism

Central and peripheral nervous system complications of COVID-19: a prospective tertiary center cohort with 3-month follow-up